Drug factory · FDA FEI 3003625059

Cayman Pharma s.r.o.

Prace 657, Neratovice, Czech Republic

Czech Republic: 1

Problems found, fixed voluntarily at FDA's last inspection, Jul 28, 2022.

Voluntary Action Indicated: inspectors found problems, but not serious enough for FDA to take action. The company is expected to fix them.

4 drug inspections on record since 2011: 1 with no problems, 3 with problems fixed voluntarily, 0 with FDA action.

What it does, for whom

DrugRoleForNDC
EpoprostenolMakes the active ingredient Actelion Pharmaceuticals US, Inc. 66215-402, 66215-403

FDA inspection history

EndedResultProgramProblems noted
Jul 28, 2022Problems found, fixed voluntarilyDrug Quality Assurance—
Jan 30, 2020Problems found, fixed voluntarilyDrug Quality Assurance—
Mar 27, 2014No problems foundDrug Quality Assurance—
Mar 17, 2011Problems found, fixed voluntarilyDrug Quality Assurance—

Registered with FDA for: api manufacture.